SCHEMBL12734151

SCHEMBL12734151

Cc1ccc(Oc2ccc(N)c(OCc3ccccc3)c2)nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 1/20 0.41
KDM4E B2RXH2 3/20 0.40
POLB P06746 1/20 0.40
ACACB O00763 3/20 0.39
ACACA Q13085 3/20 0.39
MAPT P10636 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
PPARG P37231 1/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GAA P10253 1/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
RAB9A P51151 1/20 0.39
LTA4H P09960 1/20 0.39
MAPK14 Q16539 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
BRCA1 P38398 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12734036 0.84 FFAR1 (0.46) POLBMAPTL3MBTL1SMN1; SMN2MAPK1
SCHEMBL1677111 0.83 CA12 (0.42) LIPEACACBACACASMN1; SMN2RAB9A
SCHEMBL12734150 0.81 MEN1 (0.45) KDM4EPOLBMAPTSMN1; SMN2RAB9A
SCHEMBL30058080 0.79 MAOB (0.50) MAPTL3MBTL1SMN1; SMN2GAAMAOA
SCHEMBL647614 0.79 MAOB (0.50) MAPTL3MBTL1SMN1; SMN2GAAMAOA
SCHEMBL3995038 0.78 MAPT (0.53) LIPEMAPTL3MBTL1SMN1; SMN2MAPK1
SCHEMBL12734099 0.77 KDM4E (0.43) KDM4EPOLBACACBACACAGAA
Hydrochloric Acid SCHEMBL9732977 0.77 MAPT (0.51) LIPEMAPTL3MBTL1SMN1; SMN2MAPK1
SCHEMBL4053551 0.77 MAOB (0.59) MAPTL3MBTL1SMN1; SMN2GAAMAOA
SCHEMBL12734153 0.76 KDM4E (0.47) KDM4EPOLBMAPTSMN1; SMN2PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673942-B2 Fused ring compounds and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-18 US disclosed
US-20110098297-A1 FUSED RING COMPOUNDS AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098297-A1 FUSED RING COMPOUNDS AND USE THEREOF GCKR, GPR119, SLC5A1 LIPE 129/4885KDM4E 914/4885POLB 3867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.